연구동향 분석

Surface modification of lipid-based nanocarriers for cancer cellspecific drug targeting

김창현 이상곤 강명주 이상길 최영욱 2017년

논문상세정보
인용/피인용

' Surface modification of lipid-based nanocarriers for cancer cellspecific drug targeting' 의 참고문헌

  • pH-sensitive mPEG-Hz-cholesterol conjugates as a liposome delivery system
    Chen D J Bioact Compat Polym 25 527-542 [2010]
  • pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles
    Kim HK ACS Appl Mater Interfaces 5 5648-5658 [2013]
  • Which one performs better for targeted lung cancer combination therapy: pre-or post-bombesin-decorated nanostructured lipid carriers?
    Du J Drug Deliv 23 1799-1809 [2016]
  • Uptake and intracellular processing of targeted and nontargeted liposomes by Rat Kupffer Cells in vivo and in vitro
    Scherphof GL Ann N Y Acad Sci 446 368-384 [1985]
  • Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
    Zagar TM Int J Hyperthermia 30 285-294 [2014]
  • Tumor-targeting peptides from combinatorial libraries
    Liu R Adv Drug Deliv Rev - [2016]
  • Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas
    Yang ZZ Biomaterials 35 5226-5239 [2014]
  • Tumor targeting of functionalized lipid nanoparticles:assessment by in vivo fluorescence imaging
    Goutayer M Eur J Pharm Biopharm 75 137-147 [2010]
  • Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody
    Liu D Mol Pharm 8 2291-2301 [2011]
  • Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery
    Mo R Mater Today 19 274-283 [2016]
  • Transferrinmodified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin
    Han Y Int J Nanomedicine 9 4107-4116 [2014]
  • Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots
    Muthu MS Biomaterials 33 3494-3501 [2012]
  • The use of cell-penetrating peptides for drug delivery
    Temsamani J Drug Discov Today 9 1012-1019 [2004]
  • The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes
    Gao J Biomaterials 32 3459-3470 [2011]
  • The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma
    Iyer AK Biomaterials 32 2605-2613 [2011]
  • The dawning era of polymer therapeutics
    Duncan R Nat Rev Drug Discov 2 347-360 [2003]
  • The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study
    Ishida T Cell Mol Biol Lett 7 286-286 [2002]
  • The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
    Maeda H Adv Drug Deliv Rev 65 71-79 [2013]
  • Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers
    Torchilin VP Adv Drug Deliv Rev 60 548-558 [2008]
  • Targeting tumor-associated endothelial cells:anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth
    Wicki A Clin Cancer Res 18 454-464 [2012]
  • Targeting receptor-mediated endocytotic pathways with nanoparticles:rationale and advances
    Xu S Adv Drug Deliv Rev 65 121-138 [2013]
  • Targeting etoposide to acute myelogenous leukemia cells using nanostructured lipid carriers coated with transferrin
    Khajavinia A Nanotechnology 23 1-13 [2012]
  • Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering
    Guo Z Biomaterials 35 6106-6117 [2014]
  • Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide
    Garg A Int J Pharm 366 201-210 [2009]
  • Targeted therapy using nanotechnology:focus on cancer
    Sanna V Int J Nanomedicine 9 467-483 [2014]
  • Targeted therapies for cancer 2004
    Ross JS Am J Clin Pathol 122 598-609 [2004]
  • Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles
    Zheng J Pharm Res 31 2220-2233 [2014]
  • Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA
    Shao Z Int J Nanomedicine 10 1223-1233 [2015]
  • Targeted drug delivery via the folate receptor
    Sudimack J Adv Drug Deliv Rev 41 147-162 [2000]
  • Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma
    Yuan M Drug Deliv 23 1171-1183 [2016]
  • Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system
    Zhang S Drug Deliv 23 1838-1845 [2016]
  • Targeted delivery of doxorubicin using stealth liposomes modified with transferrin
    Li X Int J Pharm 373 116-123 [2009]
  • Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly (ethylene glycol) comodified liposomal delivery system via systemic administration
    Kuai R Mol Pharm 8 2151-2161 [2011]
  • Targeted anticancer therapy: overexpressed receptors and nanotechnology
    Akhtar MJ Clin Chim Acta 436 78-92 [2014]
  • Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEGlipid
    Hatakeyama H Biomaterials 32 4306-4316 [2011]
  • Synthesis, characterization and radiolabeling of folic acid modified nanostructured lipid carriers as a contrast agent and drug delivery system
    Ucar E Appl Radiat Isot 119 72-79 [2017]
  • Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome
    Negussie AH J Control Release 143 265-273 [2010]
  • Surface-modification of RIPL peptide-conjugated liposomes to achieve steric stabilization and pH sensitivity
    Kwon YH J Nanosci Nanotechnol 17 1008-1017 [2017]
  • Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity
    Biswas S Eur J Pharm Biopharm 84 517-525 [2013]
  • Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro
    Wan F Int J Pharm 359 104-110 [2008]
  • Strategies for the intracellular delivery of nanoparticles
    Chou LY Chem Soc Rev 40 233-245 [2011]
  • Stimuli-responsive nanoparticles for targeting the tumor microenvironment
    Du J J Control Release 219 205-214 [2015]
  • Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting
    Li SD J Control Release 145 178-181 [2010]
  • Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
    Immordino ML Int J Nanomedicine 1 297-315 [2006]
  • Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes
    Dai W Pharm Res 29 2902-2911 [2012]
  • Solid lipid nanoparticles: production, characterization and applications
    Mehnert W Adv Drug Deliv Rev 47 165-196 [2001]
  • Solid lipid nanoparticles for parenteral drug delivery
    Wissing SA Adv Drug Deliv Rev 56 1257-1272 [2004]
  • Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations
    Müller RH Adv Drug Deliv Rev 54 S131-S155 [2002]
  • Sheddable coatings for long-circulating nanoparticles
    Romberg B Pharm Res 25 55-71 [2008]
  • Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin
    Jiang J Eur J Pharm Biopharm 76 170-178 [2010]
  • Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells
    Zhang XG Int J Pharm 361 239-244 [2008]
  • Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response
    Zhang Q Mol Pharm 13 1800-1808 [2016]
  • Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment
    Hobbs SK Proc Natl Acad Sci U S A 95 4607-4612 [1998]
  • Reductiontriggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating
    Oumzil K J Control Release 151 123-130 [2011]
  • Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    Gordon AN J Clin Oncol 19 3312-3322 [2001]
  • Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier
    Fillebeen C J Biol Chem 274 7011-7017 [1999]
  • Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma
    Gill PS J Clin Oncol 14 2353-2364 [1996]
  • RNAi-mediated gene knockdown and antiangiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system
    Sakurai Y J Control Release 173 110-118 [2014]
  • RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells
    Kang MH Eur J Pharm Biopharm 87 489-499 [2014]
  • RGDmodified pH-sensitive liposomes for docetaxel tumor targeting
    Chang M Colloids Surf B Biointerf 129 175-182 [2015]
  • RGDconjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells
    Shan D Drug Deliv Transl Res 5 15-26 [2015]
  • Protein resistance of PEG-functionalized dendronized surfaces: effect of PEG molecular weight and dendron generation
    Benhabbour SR Macromolecules 41 4817-4823 [2008]
  • Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers
    Shehata T Int J Pharm 359 272-279 [2008]
  • Principles in the design of ligand-targeted cancer therapeutics and imaging agents
    Srinivasarao M Nat Rev Drug Discov 14 203-219 [2015]
  • Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel
    Immordino ML J Control Release 91 417-429 [2003]
  • Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems
    Üner M Pharmazie 61 375-386 [2006]
  • Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers
    Li X J Pharm Pharmacol 61 1485-1492 [2009]
  • Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection
    Bao A Int J Pharm 316 162-169 [2006]
  • Phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer
    Fishman MN J Clin Oncol 22 2110-2110 [2004]
  • Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)
    Gaillard PJ PloS ONE 9 e82331- [2014]
  • Pharmacokinetics and tissue distribution of idarubicinloaded solid lipid nanoparticles after duodenal administration to rats
    Zara GP J Pharm Sci 91 1324-1333 [2002]
  • Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent
    Accardo A Int J Nanomedicine 7 2007-2017 [2012]
  • Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo
    Cai L Int J Nanomedicine 7 4499-4510 [2012]
  • Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides
    Remaut K J Control Release 117 256-266 [2007]
  • Past and future perspectives of synthetic peptide libraries
    Marasco D Curr Protein Pept Sci 9 447-467 [2008]
  • Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
    Liu Y Biomaterials 35 4835-4847 [2014]
  • PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles
    Mishra S Eur J Cell Biol 83 97-111 [2004]
  • PEGylation and its impact on the design of new protein-based medicines
    Ginn C Future Med Chem 6 1829-1846 [2014]
  • PEGylated nanostructured lipid carriers loaded with 10- hydroxycamptothecin: an efficient carrier with enhanced anti- tumour effects against lung cancer
    Zhang X J Pharm Pharmacol 60 1077-1087 [2008]
  • PEGylated nanomedicines:recent progress and remaining concerns
    Vllasaliu D Expert Opin Drug Deliv 11 139-154 [2014]
  • Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors
    Drummond DC Pharmacol Rev 51 691-744 [1999]
  • Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
    Owens DE Int J Pharm 307 93-102 [2006]
  • Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma
    Iwase Y Mol Pharm 8 330-337 [2011]
  • Octaargininemodified multifunctional envelope-type nano device for siRNA
    Nakamura Y J Control Release 11 360-367 [2007]
  • Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer
    Biswas S Cancer Lett 335 191-200 [2013]
  • Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells
    Chen Y Mol Pharm 6 696-705 [2009]
  • Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy
    Song S Drug Deliv 23 1404-1408 [2016]
  • Novel PEG-matrix metalloproteinase-2 cleavable peptidelipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting
    Terada T J Control Release 111 333-342 [2006]
  • Non-stealth and stealth solid lipid nanoparticles (SLN)carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats
    Fundarò A Pharmacol Res 42 337-343 [2000]
  • Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
    Sinha R Mol Cancer Ther 5 1909-1917 [2006]
  • Nanostructured lipid matrices for improved microencapsulation of drugs
    Müller RH Int J Pharm 242 121-128 [2002]
  • Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies
    Bondì ML Drug Deliv 14 61-67 [2007]
  • Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA
    Taratula O J Control Release 171 349-357 [2013]
  • Nanostructured lipid carrier (NLC) a modern approach for topical delivery: a review
    Patel DK World J Pharm Pharma Sci 2 921-938 [2013]
  • Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake
    Walkey CD J Am Chem Soc 134 2139-2147 [2012]
  • Nanoparticle and targeted systems for cancer therapy
    Brannon-Peppas L Adv Drug Deliv Rev 64 206-212 [2012]
  • Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications
    Wicki A J Control Release 200 138-157 [2015]
  • Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
    Torchilin VP Nat Rev Drug Discov 13 813-827 [2014]
  • Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma
    Liu Y ACS Appl Mater Interfaces 7 16792-16801 [2015]
  • Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
    Torchilin VP Eur J Pharm Biopharm 71 431-444 [2009]
  • Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity
    Koren E J Control Release 160 264-273 [2012]
  • Multi-functional vesicles for cancer therapy: the ultimate magic bullet
    Tavano L Colloids Surf B Biointerf 147 161-171 [2016]
  • Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia
    Al-Ahmady ZS J Control Release 196 332-343 [2014]
  • Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent
    Lozano N Int J Pharm 482 2-10 [2015]
  • Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice
    Gupta B Cancer Immunol Immunother 56 1215-1223 [2007]
  • Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting
    Zhu L ACS Nano 6 3491-3498 [2012]
  • Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors
    McNeeley KM Biomaterials 30 3986-3995 [2009]
  • Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug
    Jain A J Control Release 148 359-367 [2010]
  • MMP-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer
    Kulkarni PS Mol Pharm 11 2390-2399 [2014]
  • Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing
    Gao J Biomaterials 31 2655-2664 [2010]
  • Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
    He Y Int J Nanomedicine 5 697-705 [2010]
  • Long circulating poly (ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors
    Khalid MN Pharm Res 23 752-758 [2006]
  • Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals
    Qin Y Int J Pharm 420 304-312 [2011]
  • Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery
    Qin Y Int J Pharm 419 85-95 [2011]
  • Lipid nanoparticles for parenteral delivery of actives
    Joshi MD Eur J Pharm Biopharm 71 161-172 [2009]
  • Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
    Pardeike J Int J Pharm 366 170-184 [2009]
  • Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery
    Chen H Eur J Pharm Sci 40 94-102 [2010]
  • Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas
    Chen H Eur J Pharm Sci 44 164-173 [2011]
  • Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation
    Iwamaru Y J Neurochem 107 636-646 [2008]
  • Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2
    Demeule M J Neurochem 106 1534-1544 [2008]
  • Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells
    Bruun J Int J Nanomedicine 10 5995-6008 [2015]
  • Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects
    Maruyama K Adv Drug Deliv Rev 63 161-169 [2011]
  • Increased tumor targeted delivery using a multistage liposome system functionalized with RGD TAT and cleavable PEG
    Mei L Int J Pharm 468 26-38 [2014]
  • Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrinmodified liposomes
    Koshkaryev A Cancer Biol Ther 13 50-60 [2012]
  • In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel
    Chen DB Chem Pharm Bull 49 1444-1447 [2001]
  • In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer modified liposomes loaded with docetaxel
    Li X Int J Nanomedicine 6 1167-1184 [2011]
  • In vitro and in vivo antitumor effects of folate-targeted ursolic acid Stealth liposome
    Yang G J Agric Food Chem 62 2207-2215 [2014]
  • Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas
    Amin M Int J Pharm 458 324-333 [2013]
  • Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide
    Chen X J Controll Release 145 17-25 [2010]
  • Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
    Üner M Int J Nanomedicine 2 289-300 [2007]
  • Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma
    Bidlingmaier S Cancer Res 69 1570-1577 [2009]
  • Hypoxia targeted siRNA delivery
    Perche F Angew Chem Int Ed Engl 53 3362-3366 [2014]
  • Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy
    Cai D Biomaterials 35 2283-2294 [2014]
  • Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells
    Tran TH Carbohydr Polym 114 407-415 [2014]
  • Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer
    Yang XY Cancer Lett 334 338-345 [2013]
  • Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
    Ravar F J Control Release 229 10-22 [2016]
  • Hyaluronic acid-coated liposomes for active targeting of gemcitabine
    Arpicco S Eur J Pharm Biopharm 85 373-380 [2013]
  • Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
    Mattheolabakis G J Drug Target 23 605-618 [2015]
  • Hyaluronic acid (hyaluronan): a review
    Necas J Vet Med 53 397-411 [2008]
  • Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells
    Landesman-Milo D Cancer Lett 334 221-227 [2013]
  • High tumor penetration of paclitaxel loaded pH sensitive cleavable liposomes by depletion of tumor collagen I in breast cancer
    Zhang L ACS Appl Mater Interfaces 7 9691-9701 [2015]
  • Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage
    Shmeeda H J Control Release 136 155-160 [2009]
  • Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin
    Wei M Eur J Pharm Sci 46 131-141 [2012]
  • Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery
    Chen J J Mater Chem 22 5770-5783 [2012]
  • Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
    Jain A Colloids Surf B Biointerf 134 47-58 [2015]
  • GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation
    Cheng L Int J Nanomedicine 9 921-935 [2014]
  • Folic acidtethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation
    Kang MJ Int J Nanomedicine 8 1155-1165 [2013]
  • Folate-targeted chemotherapy
    Leamon CP Adv Drug Deliv Rev 56 8 1127-1141 [2004]
  • Folate-mediated solid–liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol)
    Wu L Drug Dev Ind Pharm 36 439-448 [2010]
  • Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting
    Ye P Int J Nanomedicine 9 2167-2178 [2014]
  • Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo
    Zhu Y Pharm Res 31 3289-3330 [2014]
  • Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery
    Gullotti E Mol Pharm 6 1041-1051 [2009]
  • Exploiting tumour hypoxia in cancer treatment
    Brown JM Nat Rev Cancer 4 437-447 [2004]
  • Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells
    Mohammadi Ghalaei P J Drug Deliv 7 1-7 [2014]
  • Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies
    Reddy LH AAPS J 6 55-64 [2004]
  • Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy
    Paliwal SR Mol Pharm 9 176-186 [2011]
  • Enzymeresponsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity
    Wan Y Biomaterials 34 3020-3030 [2013]
  • Enzyme-responsive nanoparticles for drug release and diagnostics
    De La Rica R Adv Drug Deliv Rev 64 967-978 [2012]
  • Enzyme-responsive nanomaterials for controlled drug delivery
    Hu Q Nanoscale 6 12273-12286 [2014]
  • Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy
    Qu CY Int J Nanomedicine 10 3911-3920 [2015]
  • Efficacy of interleukin-13 receptor–targeted liposomal doxorubicin in the intracranial brain tumor model
    Madhankumar AB Mol Cancer Ther 8 648-654 [2009]
  • Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer
    Wang RH Oncol Rep 33 783-791 [2015]
  • Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon
    Chen D Int J Nanomedicine 6 2053-2061 [2011]
  • Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells
    Kobayashi T Int J Pharm 329 94-102 [2007]
  • Effect of octreotide–polyethylene glycol (100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine
    Su Z Mol Pharm 8 1641-1651 [2011]
  • Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization
    Su Z Int J Pharm 447 281-292 [2013]
  • EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma
    Gao J Biomaterials 33 270-282 [2012]
  • Dysregulated pH: a perfect storm for cancer progression
    Webb BA Nat Rev Cancer 11 671-677 [2011]
  • Dualfunctional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells
    Zhang X Biomaterials 33 7103-7114 [2012]
  • Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery
    Kibria G J Control Release 153 141-148 [2011]
  • Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress
    Lammers T J Control Release 161 175-187 [2012]
  • Drug delivery
    Navarro G 157-187 [2014]
  • Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice
    Hong RL Clin Cancer Res 5 3645-3652 [1999]
  • Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid
    Hatakeyama H Gene Ther 14 68-77 [2007]
  • Design of multifunctional liposomal nanocarriers for folate receptor-specific intracellular drug delivery
    Kang MH Mol Pharm 12 4200-4213 [2015]
  • Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells
    Shmeeda H J Control Release 146 76-83 [2010]
  • Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide
    Li Y ACS Appl Mater Interfaces 8 26613-26621 [2016]
  • Decaarginine-PEG-liposome enhanced transfection efficiency and function of arginine length and PEG
    Furuhata M Int J Pharm 371 40-46 [2009]
  • Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery
    Mishra B Nanomedicine 6 9-24 [2010]
  • Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells
    Shen H Theranostics 5 755-771 [2015]
  • Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer
    Xu X Asian Pac J Cancer Prev 14 2591-2594 [2013]
  • Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker
    Hou C Nucl Med Biol 33 203-209 [2006]
  • Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronangrafted liposomes
    Qhattal HSS Mol Pharm 8 1233-1246 [2011]
  • Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer
    Gerweck LE Cancer Res 56 1194-1198 [1996]
  • Cell-penetrating peptides—mechanisms of cellular uptake and generation of delivery systems
    Trabulo S Pharmaceuticals 3 961-993 [2010]
  • Cell-penetrating peptides: design, synthesis, and applications
    Copolovici DM ACS Nano 8 1972-1994 [2014]
  • Cell penetrating peptides as an innovative approach for drug delivery; then, present and the future
    Santosh Bashyal Journal of Pharmaceutical Investigation 46 3 205-220 [2016]
  • Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology
    Bertrand N Adv Drug Deliv Rev 66 2-25 [2014]
  • Cancer chemotherapy with lipid-based nanocarriers
    Liu D Crit Rev Ther Drug Carrier Syst 27 371-417 [2010]
  • CD44antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma
    Wang L Biomaterials 33 5107-5114 [2012]
  • Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model
    Rodriguez BL Mol Pharm 10 2404-2415 [2013]
  • Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model
    Yuan L Int J Nanomedicine 8 4339-4350 [2013]
  • Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice
    Kim IY J Control Release 140 55-60 [2009]
  • Antibody-mediated targeting of the transferrin receptor in cancer cells
    Luria-Pérez R Boletín Médico del Hospital Infantil de México 73 372-379 [2016]
  • Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells
    Banerjee R Int J Cancer 112 693-700 [2004]
  • An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor
    Chono S J Control Release 131 64-69 [2008]
  • An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery
    Ding Y Int J Nanomedicine 10 6199-6214 [2015]
  • Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy
    Fan Zeng Journal of Pharmaceutical Investigation 44 7 493-504 [2014]
  • Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes
    Dams ET J Pharmacol Exp Ther 292 1071-1079 [2000]
  • A systematic in vitro investigation on poly-arginine modified nanostructured lipid carrier: pharmaceutical characteristics, cellular uptake, mechanisms and cytotoxicity
    Sun M Asian J Pharm Sci 12 51-58 [2016]
  • A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
    Steichen SD Eur J Pharm Sci 48 416-427 [2013]
  • A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
    Awada A Ann Oncol 25 824-831 [2014]
  • A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors
    Mamot C J Clin Oncol 29 3029-3029 [2011]
  • A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
    Sankhala KK J Clin Oncol 27 2535- [2009]
  • A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models
    Zhang J Mol Pharm 7 1159-1168 [2010]
  • A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy
    Paliwal SR Curr Cancer Drug Targets 10 343-353 [2010]
  • A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo
    Shi C Biomed Pharmacother 69 191-200 [2015]
  • A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
    Mansour AM Cancer Res 63 4062-4066 [2003]
  • A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
    Ko AH Br J Cancer 109 920-925 [2013]
  • A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes
    Tang J Acta Pharm Sin B 4 67-73 [2014]